Colorectal cancer: is the incidence rising in young Iraqi patients?
Shatha Yousif SHEET , Anwar K SHEIKHA , Ahmed M SAEED , Hazha Abdulla M AMEEN
Asia-pacific Journal of Clinical Oncology 8 ( 4) 380 -381
2
2012
P01.035 Nivolumab and Temozolomide (TMZ) vs TMZ alone in newly diagnosed elderly patients (pts) with Glioblastoma (GBM) (NUTMEG): Trial in progress
M Khasraw , K McDonald , S Yip , R G Verhaak
Neuro-oncology 20 236 -236
2018
Validation of cancer-type-dependent benefit from immune checkpoint blockade in TMB-H tumors identified by the FoundationOne CDx assay
DJ McGrail , PG Pilié , NU Rashid , L Voorwerk
Annals of Oncology 33 ( 11) 1204 -1206
2
2022
MEDICAL AND NEURO-ONCOLOGY
G Prithviraj , S Sommers , Robin Jump , Balazs Halmos
Neuro-oncology 13 ( Suppl 3) iii41 -iii68
2011
THE AGEING, CHRONIC DISEASE AND INJURY STUDY: EPIDEMIOLOGY OF HIP FRACTURES ACROSS WESTERN VICTORIA, AUSTRALIA
K Holloway , MA Sajjad , M Mohcbbi , M Kotowicz
OSTEOPOROSIS INTERNATIONAL 27 S732 -S733
2016
P11. 65. B GBM AGILE: A global, phase 2/3 adaptive platform trial to evaluate multiple treatment regimens in newly diagnosed and recurrent glioblastoma
M Weller , B Ellingson , B Alexander , P Wen
Neuro-Oncology 24 ( Supplement_2) ii73 -ii73
1
2022
P11. 29. B UPDATE ON GBM AGILE: A GLOBAL, PHASE 2/3 ADAPTIVE PLATFORM TRIAL TO EVALUATE MULTIPLE REGIMENS IN NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA
M Weller , B Alexander , D Berry , N Blondin
Neuro-oncology (Charlottesville, Va.) 25 ( Supplement_2) ii79 -ii80
2023
Saltz L
R Abrams , R Afonso , N Alessi , C Alfaro
Phase 1 study of M7824, a bifunctional fusion protein targeting TGF-β and PD-L1, among patients with recurrent glioblastoma
M Khasraw ,
Neuro Oncol 20
3
2018
Process Development and Manufacturing: NEW APPROACHES FOR EXPANDING GLIOBLASTOMA INFILTRATING LYMPHOCYTES
P Noldner , Y Zhou , RE Parrott , P Fecci
Cytotherapy 25 ( 6) S195 -S195
2023
Le-Petross H Lev D Lewis P Lyratzopoulos G
J Madewell , P Allgood , R Andtbacka , M Balbay
Rezidivmuster bei Patienten mit anaplastischem Glioma mit einer IDH1/2-Mutation
M Back , D Jayamanne , D Brazier , A Newey
Strahlentherapie und Onkologie 196 31 -39
2020
Intracranial haemorrhage: 12 case reports
M Khasraw
Reactions 1400 5 -5
2012
Our thanks to those who have helped with this issue of Expert Review of Gastroenterology & Hepatology. Listed below are the authors, referees and others who have kindly given their time, effort and expertise; their generosity has helped establish this publication.
L Abenavoli , G Actis , S Adler , E Allen-Vercoe
Dual 18F-Fluorodeoxyglucose/68Gallium DOTATATE (FDG/DOTA) PET Predicts Overall Survival in Neuroendocrine Tumours (NET)
D Chan , D Bailey , G Schembri , E Bernard
NEUROENDOCRINOLOGY 103 55 -55
2016
Dual somatostatin receptor/FDG PET/CT imaging in metastatic neuroendocrine tumours: proposal for a novel grading scheme with prognostic significance. Theranostics. 2017; 7 (5): 1149–1158
DL Chan , N Pavlakis , GP Schembri , EJ Bernard
DOI: https://doi. org/10.7150/thno 18068 1149 -1158
15
2020
Machinelearning prediction of cancer survival: a retrospective study using electronic administrative records and a cancer registry. BMJ Open. 2014; 4 (3): e004007
S Gupta , T Tran , W Luo , D Phung
Machine learning for personalized medicine: predicting primary myocardial infarction from electronic health records. AI Mag 33 ( 4) 33 -45
9
2012
Our thanks to those who have helped with this issue of Expert Review of Anticancer Therapy. Listed below are the authors, referees and others who have kindly given their time, effort and expertise; their generosity has helped establish this publication.
R Abrams , R Afonso , N Alessi , C Alfaro
P27. 11. A GLOBAL EXPANSION OF GBM AGILE: A PHASE 2/3 ADAPTIVE PLATFORM TRIAL TO EVALUATE MULTIPLE REGIMENS IN NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA
M Weller , D Berry , N Blondin , B Boulmay
Neuro-Oncology 26 ( Supplement_5) v139 -v139
2024
OS09. 7. A GBM AGILE PLATFORM TRIAL FOR NEWLY DIAGNOSED AND RECURRENT GBM: RESULTS OF FIRST EXPERIMENTAL ARM, REGORAFENIB
A Lassman , B Alexander , D Berry , M Buxton
Neuro-Oncology 26 ( Supplement_5) v26 -v27
2024